Heyholder
‹ Activism Filings

ST PHARM CO., LTD. Q3 operating profit KRW 15.7 billion, up 6.6% from a year earlier

ST PHARM CO., LTD.· Periodic Report

AI summary · Not investment advice

STPharm sold KRW 97.6 billion worth in Q3 and earned KRW 15.7 billion from its main business, up 6.6% from a year earlier and down 14.3% from the prior quarter.

Operating profit · 3 months

KRW 15.7 billion

Key facts

Revenue (3 months)
KRW 97.6 billion
Net income (3 months)
KRW 910.3 million
Period
Q3 (cumulative Jan 1, 2026 ~ Sep 30, 2026)
Revenue (prior-year 3 months)
KRW 81.9 billion
Revenue (year to date)
KRW 273.0 billion
Operating profit (prior-year 3 months)
KRW 14.7 billion
Operating profit (year to date)
KRW 45.5 billion
Net income (prior-year 3 months)
KRW 17.5 billion
Net income (year to date)
KRW 29.3 billion

Commentary

AI commentary · Not investment advice

What happened

STPharm reported its consolidated results for the third quarter of 2026. Sales for the latest 3 months were KRW 97.58 billion. That is up 19.1% from the same 3 months a year earlier (KRW 81.91 billion) and down 10.1% from the previous quarter.

In the company's terms

Operating profit (profit from its main business) for the 3 months was KRW 15.69 billion. That is up 6.6% from a year earlier (KRW 14.72 billion) and down 14.3% from the previous quarter. Net income (final profit after taxes and other costs) was KRW 910.3 million. That is down 94.8% from a year earlier (KRW 17.46 billion) and down 93.1% from the previous quarter.

What changes for shareholders

For the year to date, sales were KRW 273.02 billion. Operating profit was KRW 45.53 billion, and net income was KRW 29.26 billion.

Comments

No comments yet

Comments from shareholders will appear here.